Stockscreener 앱 받기
5.57
1.09%
0.06
시간 외 거래:
5.47
-0.10
-1.80%
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
Noble Financial Has Positive Forecast for UNCY Q3 Earnings - MarketBeat
Research Analysts Set Expectations for UNCY Q3 Earnings - MarketBeat
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Nantahala Capital (UNCY) discloses 2.81M-share, 9.99% holding in Unicycive - Stock Titan
Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake - Stock Titan
Noble Financial Has Pessimistic View of UNCY Q2 Earnings - MarketBeat
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - Benzinga
B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Unicycive Therapeutics Releases Q2 2026 Financial Results - news.alphastreet.com
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.5, Implies 550% Upside - TradingView
Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results - MarketBeat
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.7, Implies 554% Upside - TradingView
Unicycive Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Unicycive Therapeutics Q2 Results: EPS beats estimates by 82% - scanx.trade
Form 8K Unicycive Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Unicycive Reports Q2 2026 Results: $1.7M Net Loss, $61.4M Cash and Runway Into 2027 - TradingView
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Unicycive Reports Q2 Loss As FDA Assigns OLC Facility Inspection - Moomoo
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts - Yahoo Finance
Unicycive Therapeutics stock rises 2% on second quarter earnings beat By Investing.com - Investing.com South Africa
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Unicycive Therapeutics Reports FDA Facility Inspection Assigned for OLC Manufacturing Vendor, Plans NDA Resubmission After Successful Inspection - Quiver Quantitative
Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection - Stock Titan
Unicycive Therapeutics (UNCY) posts $14.5M H1 loss, raises $34M equity - Stock Titan
Unicycive Therapeutics, Inc. Q2 2026: Net income $(1.72M), EPS $(0.06) — 10-Q Summary - TradingView
Unicycive Therapeutics (UNCY) Earnings Date and Reports 2026 - MarketBeat
Unicycive: Solving Launch Data Challenges with Unlimited Access to Patient Data - Veeva
Unicycive Therapeutics Inc (UNCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Unicycive Therapeutics Inc (UNCY) Stock News Today - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeut - natlawreview.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday - MarketBeat
BlackRock, Inc. Expands Stake in Unicycive Therapeutics Inc (UNC - GuruFocus
BlackRock (UNCY holder) reports 5.3% Unicycive Therapeutics stake in Schedule 13G - Stock Titan
Unicycive Therapeutics (UNCY) director granted 47,941 RSUs with staged vesting - Stock Titan
Unicycive Therapeutics Inc (UNCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Unicycive Therapeutics Inc (UNCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Unicycive Therapeutics Inc (UNCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Unicycive Therapeutics, Inc. Revenue Breakdown – NASDAQ:UNCY - TradingView
Unicycive Therapeutics Inc (UNCY) Balance Sheet - TradingKey
Unicycive Therapeutics Inc (UNCY) Cash Flow - TradingKey
UNCY|Unicycive Therapeutics Inc|Price:5.185|Chg%:-0.215 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive The - The National Law Review
Unicycive Therapeutics Inc (UNCY) Income Statement - TradingKey
Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bronstein, Gewirtz & Grossman, LLC (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics Inc (UNCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Unicycive Therapeutics Inc (UNCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
UNCY|Unicycive Therapeutics Inc|Price:5.015|Chg%:-0.285 - TradingKey
Unicycive Therapeutics Inc (UNCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval - Stocktwits
Unicycive Therapeutics Inc (UNCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
1.80%
1.77%
자본화:
|
볼륨(24시간):